Literature DB >> 2065248

A clinicopathological study of the Guillain-Barré syndrome. Nine cases and literature review.

M Honavar1, J K Tharakan, R A Hughes, S Leibowitz, J B Winer.   

Abstract

The postmortem findings are reported from 9 cases of the Guillain-Barré syndrome with survival between 10 days and 1 yr. In 8 cases there was multifocal loss of myelin throughout the peripheral nervous system with relative preservation of axons. In 1 case there was predominant loss of axons. Inflammatory mononuclear cell infiltration was present in the peripheral nervous system of all cases except 1 case surviving a year. The extent and severity of cell infiltration was variable, usually being less prominent than in previous reports, and sometimes sparing nerves in which myelin destruction was severe. Vesicular dissolution of myelin noted by electron microscopy was considered to be a postmortem artefact. In cases examined within 30 days after the onset, immunohistochemical studies with monoclonal antibodies identified more leucocytes (PD7/2B11+) and T cells (UCHL1+) in the endoneurium than in cases examined later or control cases. These findings and recent single case reports indicate that the pathology of the Guillian-Barré syndrome is variable. This variability may reflect differences in pathogenesis, with greater cell-mediated immunity in some cases and greater antibody targeted macrophage-mediated demyelination in others.

Entities:  

Mesh:

Year:  1991        PMID: 2065248     DOI: 10.1093/brain/114.3.1245

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

Review 1.  Guillain-Barré syndrome.

Authors:  U Seneviratne
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

2.  Pseudoaxonal Guillain-Barré syndrome: severe demyelination mimicking axonopathy. A case with pupillary involvement.

Authors:  G N Fuller; J M Jacobs; P D Lewis; R J Lane
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-11       Impact factor: 10.154

3.  Potential role of transforming growth factor-beta 1 in terminating the immune response in patients with Guillain-Barré syndrome.

Authors:  E Sindern; K Schweppe; L M Ossege; J P Malin
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

4.  Acute motor axonal neuropathy presenting with bowel, bladder, and erectile dysfunction.

Authors:  Setsu Sawai; Ryuji Sakakibara; Tomoyuki Uchiyama; Zhi Liu; Tatsuya Yamamoto; Takashi Ito; Satoshi Kuwabara; Kazuaki Kanai; Masato Asahina; Takashi Yamanaka; Takeo Odaka; Taketo Yamaguchi; Takamichi Hattori
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

5.  Guillain-Barré syndrome revisited.

Authors:  J Winer
Journal:  BMJ       Date:  1992-01-11

6.  Total number and size distribution of motor neurons in the spinal cord of normal and EMC-virus infected mice--a stereological study.

Authors:  U J Weber; T Bock; K Buschard; B Pakkenberg
Journal:  J Anat       Date:  1997-10       Impact factor: 2.610

7.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

8.  Immunopathology and Th1/Th2 immune response of Campylobacter jejuni-induced paralysis resembling Guillain-Barré syndrome in chicken.

Authors:  Kishan K Nyati; Kashi N Prasad; Nagendra K Kharwar; Priyanka Soni; Nuzhat Husain; Vinita Agrawal; Arun K Jain
Journal:  Med Microbiol Immunol       Date:  2011-11-19       Impact factor: 3.402

9.  The Guillain-Barré syndrome: no longer a simple concept.

Authors:  P K Thomas
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

Review 10.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.